Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer (DOTA-1)

15 november 2026 uppdaterad av: Ratchapas Romrattaphan, Mahidol University

DOminant-TArgeted Stereotactic Ablative Radiotherapy in Localized Prostate Cancer: Single-fraction Phase I/II Pilot Study (DOTA-1)

This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer.

Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one fraction: 20 Gy to the whole prostate, 26 Gy to the DIL, and 15 Gy to the seminal vesicles. The aim is to deliver a brachytherapy-like ablative dose without an invasive procedure.

The primary outcome is acute genitourinary and rectal toxicity (CTCAE v5.0) within 3 months after treatment. Secondary outcomes include late toxicity, patient-reported quality of life (IPSS, IIEF, FACT-P), biochemical failure-free survival (Phoenix definition), local recurrence-free, progression-free, distant metastasis-free and overall survival, correlation of MR-radiomics with clinical outcomes, and cost-effectiveness. Patients will be followed for 5 years.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

10

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Bangkok
      • Bangkok Noi, Bangkok, Thailand, 10700
        • Rekrytering
        • Siriraj Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  1. Men ≥ 18 years old

  2. Newly diagnosed and histologically confirmed localized prostate adenocarcinoma

  3. Very low-, low-, and favorable intermediate-risk via NCCN risk group classification, defined as;

    • Gleason grade group 1 or 2
    • Clinical stage T1-T2c
    • Initial PSA < 20 ng/ml (Patient can have only one of cT2b-cT2c, Gleason grade group 2 and PSA 10-20 ng/ml)
  4. Visible dominant-intraprostatic lesion (DIL) on multi-parametric MRI defined by PI-RADS classification

  5. ECOG Performance Status 0-2 within 28 days prior to study entry

  6. Patients must be able to provide study-specific informed consent prior to study entry.

Exclusion Criteria:

  1. Direct extraprostatic extension into the adjacent structures
  2. Extraprostatic metastases or malignant nodes
  3. Large prostate volume > 60 cm3 by imaging
  4. Use of Androgen deprivation therapy
  5. Baseline IPSS > 13
  6. MRI-contraindicated patient (eg., MRI-incompatible pacemaker, metal implant)
  7. Patient with hip prosthesis which causes artifact on MR images
  8. Patient with significant predisposing comorbidity (eg. inflammatory bowel disease)
  9. Prior radiotherapy to the region of the pelvis that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
  10. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Single-fraction MR-guided SBRT

A single fraction of stereotactic body radiotherapy (SBRT) delivered on a 1.5T MR-Linac with daily MRI guidance, using IMRT with a simultaneous integrated boost. Prescribed doses: 26 Gy to the dominant intraprostatic lesion (DIL; PI-RADS 4-5 lesion on multiparametric MRI), 20 Gy to the whole prostate, and 15 Gy to the seminal vesicles. A hydrogel rectal spacer is inserted before CT/MR simulation. Before simulation and treatment, patients follow a bladder protocol (void, then drink 200-300 mL of water) and empty the rectum. No androgen deprivation therapy is given.

Andra namn:
  • Single-fraction SABR with DIL boost
  • DOTA-1 regimen

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Acute toxicity (Genitourinary and Gastrointestinal toxicity)
Tidsram: Up to 3 months after SBRT

Incidence of acute treatment-related toxicity from the date of treatment by radiotherapy up to 3 months after completion of radiotherapy, assessed using CTCAE version 5.0

Up to 3 months after SBRT

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Late toxicity (Genitourinary and Gastrointestinal toxicity)
Tidsram: From 3 months to 5 years after SBRT

Incidence of late (chronic) treatment-related toxicity from 3 months after completion of radiotherapy up to 5 years after completion of radiotherapy, assessed using CTCAE version 5.0

From 3 months to 5 years after SBRT
International Prostate Symptom Score (I-PSS)
Tidsram: Baseline and at each follow-up visit up to 5 years after SBRT

Patient-reported urinary symptoms assessed using the I-PSS. The total score ranges from 0 to 35; higher scores indicate worse urinary symptoms.

Baseline and at each follow-up visit up to 5 years after SBRT
International Index of Erectile Function (IIEF-5) score
Tidsram: Baseline and at each follow-up visit up to 5 years after SBRT

Patient-reported erectile function assessed using the IIEF-5 Score. The total score ranges from 5 to 25; higher scores indicate better erectile function.

Baseline and at each follow-up visit up to 5 years after SBRT
Functional Assessment of Cancer Therapy - Prostate (FACT-P) score
Tidsram: Baseline and at each follow-up visit up to 5 years after SBRT

Health-related quality of life assessed using the FACT-P. The total score ranges from 0 to 156; higher scores indicate better quality of life.

Baseline and at each follow-up visit up to 5 years after SBRT
Freedom from biochemical failure
Tidsram: 5 years after SBRT

Time from SBRT to biochemical failure, defined by the Phoenix criteria (PSA nadir + 2 ng/mL), estimated by the Kaplan-Meier method.

5 years after SBRT
Local recurrence-free survival
Tidsram: 5 years after SBRT

Time from SBRT to recurrence within the prostate, estimated by the Kaplan-Meier method.

5 years after SBRT
Overall survival
Tidsram: 5 years after SBRT

Time from SBRT to death from any cause, estimated by the Kaplan-Meier method.

5 years after SBRT
Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY)
Tidsram: 5 years after SBRT

Cost and utility data will be used to evaluate cost-effectiveness by calculating the incremental cost-effectiveness ratio (ICER). Uncertainty analyses will be performed using one-way sensitivity analysis, probabilistic sensitivity analysis, and threshold analysis.

5 years after SBRT

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 juni 2026

Primärt slutförande (Beräknad)

1 juni 2027

Avslutad studie (Beräknad)

1 juni 2033

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

15 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 november 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be shared outside the study team. The informed consent and ethics approval do not cover data sharing.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera